JP2016513950A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513950A5 JP2016513950A5 JP2015533454A JP2015533454A JP2016513950A5 JP 2016513950 A5 JP2016513950 A5 JP 2016513950A5 JP 2015533454 A JP2015533454 A JP 2015533454A JP 2015533454 A JP2015533454 A JP 2015533454A JP 2016513950 A5 JP2016513950 A5 JP 2016513950A5
- Authority
- JP
- Japan
- Prior art keywords
- oligomer
- monomers
- affinity region
- region consisting
- microrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000178 monomer Substances 0.000 claims 9
- 108700011259 MicroRNAs Proteins 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705668P | 2012-09-26 | 2012-09-26 | |
| DKPA201200587 | 2012-09-26 | ||
| DKPA201200587 | 2012-09-26 | ||
| US61/705,668 | 2012-09-26 | ||
| PCT/DK2013/050308 WO2014048441A1 (en) | 2012-09-26 | 2013-09-26 | Oligomers with improved off-target profile |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513950A JP2016513950A (ja) | 2016-05-19 |
| JP2016513950A5 true JP2016513950A5 (enExample) | 2017-06-22 |
| JP6352269B2 JP6352269B2 (ja) | 2018-07-04 |
Family
ID=50387035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015533454A Active JP6352269B2 (ja) | 2012-09-26 | 2013-09-26 | オフターゲットプロファイルの改善されたオリゴマー |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9725721B2 (enExample) |
| EP (1) | EP2900822B1 (enExample) |
| JP (1) | JP6352269B2 (enExample) |
| CN (1) | CN104955950B (enExample) |
| AU (1) | AU2013324716B2 (enExample) |
| CA (1) | CA2886116C (enExample) |
| WO (1) | WO2014048441A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2702155B9 (en) | 2011-04-25 | 2020-01-01 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| PH12023550488A1 (en) | 2012-04-25 | 2024-06-24 | Sanofi Sa | Microrna compounds and methods for modulating mir-21 activity |
| JP6430945B2 (ja) | 2012-10-02 | 2018-11-28 | センテナリ インスティテュート オブ キャンサー メディシン アンド セル バイオロジーＣｅｎｔｅｎａｒｙ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｃａｎｃｅｒ Ｍｅｄｉｃｉｎｅ Ａｎｄ Ｃｅｌｌ Ｂｉｏｌｏｇｙ | Ｒｎａ活性及び血管透過性の調節 |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| TW201446791A (zh) | 2013-05-01 | 2014-12-16 | Regulus Therapeutics Inc | 用於調節mir-122之微小rna化合物及方法 |
| WO2015061536A1 (en) | 2013-10-25 | 2015-04-30 | Regulus Therapeutics Inc. | Microrna compounds and methods for modulating mir-21 activity |
| KR102633955B1 (ko) | 2014-06-13 | 2024-02-06 | 도레이 카부시키가이샤 | 대장암의 검출 키트 또는 디바이스 및 검출 방법 |
| JP6804975B2 (ja) * | 2014-06-13 | 2020-12-23 | 東レ株式会社 | 乳がんの検出キット又はデバイス及び検出方法 |
| CN106460068B (zh) * | 2014-06-16 | 2024-08-23 | 东丽株式会社 | 胃癌的检测试剂盒或装置以及检测方法 |
| CN119842899A (zh) | 2014-06-18 | 2025-04-18 | 东丽株式会社 | 肝癌的检测试剂盒或装置以及检测方法 |
| JP6385732B2 (ja) * | 2014-06-27 | 2018-09-05 | 国立大学法人北海道大学 | 免疫応答制御剤 |
| RU2017105342A (ru) | 2014-08-07 | 2018-09-13 | Регулус Терапьютикс Инк. | НАЦЕЛИВАНИЕ НА микроРНК ПРИ РАССТРОЙСТВАХ ОБМЕНА ВЕЩЕСТВ |
| BR112017003608B1 (pt) * | 2014-09-16 | 2023-11-07 | Toray Industries, Inc | MÉTODO PARA A ANÁLISE COMPARATIVA DO NÍVEL DE EXPRESSÃO DE miRNA(S) ALVO(S) E CHIP PARA ANÁLISE DA EXPRESSÃO DE miRNA |
| WO2016115609A1 (en) * | 2015-01-20 | 2016-07-28 | Katholieke Universiteit Leuven | Colon cancer |
| WO2016137235A2 (ko) | 2015-02-25 | 2016-09-01 | (주)바이오니아 | 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물 |
| CN104826133B (zh) * | 2015-05-01 | 2020-11-24 | 北京博奥医学检验所有限公司 | 一种与肺腺癌有关的miRNA及其药物组合物 |
| CN107058470B (zh) * | 2016-11-03 | 2020-09-01 | 中国人民解放军陆军军医大学 | 一种通过联合miR-136和miR-4791预测急性高山病发病风险的诊断试剂盒 |
| CN107058472B (zh) * | 2016-11-03 | 2020-10-27 | 中国人民解放军陆军军医大学 | 一种通过四种血浆microRNA联合诊断急性高山病的诊断试剂盒 |
| CN107058471B (zh) * | 2016-11-03 | 2020-09-01 | 中国人民解放军陆军军医大学 | 一种通过四种microRNA生物标志物联合预测急性高山病发病风险的试剂盒 |
| CN107058475B (zh) * | 2016-11-03 | 2020-10-27 | 中国人民解放军陆军军医大学 | 一种联合miR-676、miR-181b和miR-193b诊断急性高山病的试剂盒 |
| CN107058474B (zh) * | 2016-11-03 | 2020-09-01 | 中国人民解放军陆军军医大学 | 一种通过血浆microRNA-3591-3p诊断急性高山病的诊断试剂盒 |
| CN107058473B (zh) * | 2016-11-03 | 2020-10-27 | 中国人民解放军陆军军医大学 | 一种联合miR-676、miR-181b和miR-3591诊断急性高山病的试剂盒 |
| CN108251422A (zh) * | 2016-12-29 | 2018-07-06 | 昆山彭济凯丰生物科技有限公司 | 通过miR-6069进行抗癌的方法和药物及其应用 |
| CN108295086B (zh) * | 2017-01-13 | 2021-11-02 | 昆山彭济凯丰生物科技有限公司 | 通过miR-4418进行抗癌的方法和药物及其应用 |
| CN108295260A (zh) * | 2017-01-13 | 2018-07-20 | 彭长庚 | 通过miR-1915-3p进行抗癌的方法和药物及其应用 |
| CN108310381A (zh) * | 2017-01-16 | 2018-07-24 | 昆山彭济凯丰生物科技有限公司 | 通过miR-6511b-3p进行抗癌的方法和药物及其应用 |
| CN107502609A (zh) * | 2017-09-08 | 2017-12-22 | 中国科学院深圳先进技术研究院 | 一种靶向cJun信号通路的miRNA及其制备方法和应用 |
| KR102070969B1 (ko) * | 2018-04-10 | 2020-01-29 | 한국한의학연구원 | 통증 판별용 마커 |
| CN112400020B (zh) | 2018-05-08 | 2024-11-19 | 莱古路斯治疗法股份有限公司 | 作为具有hcv抗病毒活性与降低的高胆红素血症副作用的mir-122抑制剂的galnac缀合的经修饰的寡核苷酸 |
| CN109468375B (zh) * | 2018-12-28 | 2021-05-14 | 固安博健生物技术有限公司 | 分子标志物在骨质疏松症中的应用 |
| CN113993588B (zh) * | 2019-06-05 | 2024-03-01 | 癌症干细胞科技公司 | 癌治疗剂 |
| CN111073973A (zh) * | 2019-12-10 | 2020-04-28 | 石河子大学 | 一种用于早期诊断2型糖尿病的microRNA序列及其应用 |
| CN114767703B (zh) * | 2022-06-20 | 2022-09-02 | 山东恺悌生物制品有限公司 | miR-4311模拟物在制备肺癌治疗药物中的应用 |
| WO2025067351A2 (en) * | 2023-09-27 | 2025-04-03 | Neuro3 Therapeutics, Inc. | Novel sirna constructs, therapeutics, and modifications |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| CN100569945C (zh) * | 2003-12-23 | 2009-12-16 | 桑塔里斯制药公司 | 用于调节bcl-2的寡聚化合物 |
| KR20080068019A (ko) * | 2005-09-15 | 2008-07-22 | 산타리스 팔마 에이/에스 | 아포지단백질-ｂ100 발현 억제용 ｒｎａ 길항제 화합물 |
| AU2007323469B2 (en) | 2006-11-23 | 2014-07-24 | Guangdong Maijinjia Biotechnology Co., Ltd | Oligonucleotides for modulating target RNA activity |
| US20090137504A1 (en) * | 2006-12-21 | 2009-05-28 | Soren Morgenthaler Echwald | Microrna target site blocking oligos and uses thereof |
| CN101821390A (zh) * | 2007-06-14 | 2010-09-01 | 米尔克斯治疗有限责任公司 | 用于调节靶rna活性的寡核苷酸 |
| KR20100110298A (ko) | 2007-11-26 | 2010-10-12 | 산타리스 팔마 에이/에스 | 안드로겐 수용체를 표적화하는 ｌｎａ 길항제 |
| WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
| JP5773535B2 (ja) * | 2009-04-24 | 2015-09-02 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ | インターフェロンに非応答性のｈｃｖ患者の治療のための医薬組成物 |
| WO2011115818A1 (en) * | 2010-03-17 | 2011-09-22 | Isis Pharmaceuticals, Inc. | 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2011117353A1 (en) * | 2010-03-24 | 2011-09-29 | Mirrx Therapeutics A/S | Bivalent antisense oligonucleotides |
-
2013
- 2013-09-26 US US14/431,212 patent/US9725721B2/en active Active
- 2013-09-26 CA CA2886116A patent/CA2886116C/en active Active
- 2013-09-26 JP JP2015533454A patent/JP6352269B2/ja active Active
- 2013-09-26 AU AU2013324716A patent/AU2013324716B2/en active Active
- 2013-09-26 WO PCT/DK2013/050308 patent/WO2014048441A1/en not_active Ceased
- 2013-09-26 CN CN201380057694.6A patent/CN104955950B/zh active Active
- 2013-09-26 EP EP13842025.2A patent/EP2900822B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513950A5 (enExample) | ||
| JP2015516989A5 (enExample) | ||
| WO2014191359A9 (en) | Aptamers and use of the aptamers in the diagnosis and treatment of cancer | |
| JP2016526529A5 (enExample) | ||
| JP2015133993A5 (enExample) | ||
| JP2018512041A5 (enExample) | ||
| JP2018512110A5 (enExample) | ||
| EA201600044A1 (ru) | Композиции для интродукции рнк в клетки | |
| NZ720286A (en) | Modulation of angiopoietin-like 3 expression | |
| WO2014179627A3 (en) | Compositions and methods for modulating hbv and ttr expression | |
| EP3312281A3 (en) | Complement component c5 irna compositions and methods of use thereof | |
| BR112015021884A2 (pt) | vetores compreendendo sequências de polinucleotídeos de stuffer/agente de enchimento e métodos de uso | |
| CR20150236A (es) | Métodos para el tratamiento del síndrome de alport | |
| JP2014237817A5 (enExample) | ||
| JP2017502668A5 (enExample) | ||
| EA201791986A1 (ru) | Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза | |
| JP2015512855A5 (enExample) | ||
| DK3294756T3 (da) | Retroviral partikel, omfattende mindst to forskellige indkapslede, ikke-virale RNA'er | |
| MX2020005754A (es) | Oligonucleotidos gapmeros que comprenden un enlace internucleosido fosforoditioato. | |
| WO2016106387A3 (en) | Nucleic acid aptamers to treat histone-induced disease states | |
| JP2014532403A5 (enExample) | ||
| JP2016108250A5 (enExample) | ||
| JP2015523858A5 (enExample) | ||
| De Luca et al. | Involutions of epicentral words | |
| WO2012134135A3 (ko) | 스페르민 공중합체 및 이를 핵산 전달체로 이용하는 유전자 치료 |